Mizuho analyst Graig Suvannavejh raised the firm’s price target on Insmed (INSM) to $110 from $96 and keeps an Outperform rating on the shares. The company reported positive Phase 2b data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension, the analyst tells investors in a research note. The firm says the data “were outstanding,” positioning TPIP as a potential new standard of care. Simply put, Insmed “hit a grand slam,” contends Mizuho. The firm sees multiple opportunities for upside to estimates.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment
- Insmed price target raised to $109 from $94 at BofA
- Insmed price target raised to $120 from $90 at H.C. Wainwright
- Insmed price target raised to $119 from $107 at Wells Fargo
- Insmed price target raised to $110 from $92 at Stifel